KEVZARA
What it isIL-6 receptor antibody; rheumatoid arthritis and polymyalgia rheumatica.
Why this oneIt is the IL-6-receptor blocker specifically labeled for polymyalgia rheumatica when corticosteroids fail or cannot be tolerated.
What limits itIt suppresses CRP and fever, so infection can be masked. Neutropenia, transaminitis and GI perforation risk.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Rheumatoid arthritis | Adult | 200 mg SC q2wk | 200 mg SC q2wk | 200 mg SC q2wk |
| Polymyalgia rheumatica | Adult | 200 mg SC q2wk (with tapering corticosteroids) | 200 mg SC q2wk | 200 mg SC q2wk |
| Polyarticular juvenile idiopathic arthritis (≥63 kg) | Pediatric | 200 mg SC q2wk | 200 mg SC q2wk | 200 mg SC q2wk |
Renal Undefined
Hepatic Undefined
Pregnancy Insufficient human data; monoclonal antibody actively crosses placenta in 3rd trimester and may affect infant immune response
Lactation No data on presence in human milk; maternal IgG is present in milk
⚠ BOXED WARNING
Cost, est. cash$1,000–$15,000+/month
Generic entry2033 est. (biosimilar)
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySerious infection, cytopenias, hepatic injury and malignancy risk require laboratory and clinical monitoring.

Open Sarilumab in the interactive console ↗
